Market Introduction
Radiotherapy is majorly used to control the growth of the tumour and with the minimum exposure to the surrounding normal and healthy tissue. Radiotherapy uses high-energy radiation, generally x-rays, to destroy the cancer cells and treat tumours in the prostate, breast, head & neck, lung and at any other parts in the body where radiation treatment is indicated. Advances in radiotherapy have been made in the last few years, as improvements in imaging modalities, powerful computers and software and delivery systems have enabled technologies.
Thus, the rising prevalence of cancer across the region is expected to create a significant demand for radiotherapy in the coming years, which is further anticipated to drive the radiotherapy market.
During the COVID-19 era, Chinese hospitals have developed a system that enables vulnerable cancer patients to continue to receive high-quality medical care, optimizing their survival whilst protecting them. This includes the use of digital quick codes, fever clinics, and optimal scheduling. Running of high patient volume radiation oncology department during COVID-19 crisis in India, strategies were taken in the form of following areas were steps need to be taken to decrease the risk of infection, categorize treatment on the basis of priority, radiotherapy schedules modification, academic meetings, and management of COVID positive patient/personnel in radiation oncology department. Thus, radiotherapy market is moderately impacted due to Covid -19.
Market Overview and Dynamics
The Radiotherapy market in Asia Pacific is expected to grow from US$ 1,242.1 million in 2021 to US$ 1,938.6 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028. In the last few years, there has been an increase in investments on research activities focused on early detection of cancer, as well as development of new technologies for cancer treatment and management. Along with this, the education & research centers, healthcare authorities, and market players are actively participating in number of conferences and symposiums for sharing the knowledge, as well as showcasing new technologies. In addition, such programs are prominently contributing to spread awareness about radiation therapy, which will eventually drive the market during the forecast period. Furthermore, in November 2018, Beijing Allcure Medical Technology Co. and Mevion Medical Systems jointly conducted a conference on Trends in Compact Proton Therapy in China at the annual meeting of the China Society for Radiation Oncology. Such conferences and meetings are likely to boost the innovation and new product developments across the region. In addition, the symposiums are anticipated to contribute to the product enhancements, which will eventually drive the radiotherapy market by 2028.
Key Market Segments
In terms of type, the external-beam radiation therapy segment accounted for the largest share of the Asia Pacific radiotherapy market in 2020. In terms of product, the external beam radiotherapy products segment accounted for the largest share of the Asia Pacific radiotherapy market in 2020. In terms of application, the breast cancer segment accounted for the largest share of the Asia Pacific radiotherapy market in 2020. In terms of end user, the hospitals segment held a larger market share of the radiotherapy market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Radiotherapy market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Siemens Healthineers AG, Accuray Incorporated, Sumitomo Heavy Industries, Ltd., Elekta AB, Hitachi, Ltd., Koninklijke Philips N.V., Brainlab AG, Mevion Medical Systems, and Varian Medical Systems, Inc.
Reasons to buy report
- To understand the Asia Pacific Radiotherapy market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific Radiotherapy market
- Efficiently plan M&A and partnership deals in Asia Pacific Radiotherapy market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific Radiotherapy market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.
ASIA PACIFIC RADIOTHERAPY MARKET SEGMENTATION
By Type
- External-Beam Radiation Therapy
- Internal Radiation Therapy
- Systemic Radiotherapy/Radiopharmaceuticals
By Product
- External Beam Radiotherapy Products
- Internal Radiotherapy Products
- Radiotherapy Software
- Others
By Application
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Liver Cancer
- Thyroid Cancer
- Lymphoma
- Spine Cancer
- Brain Cancer
- Others
By End User
- Hospitals
- Specialty Clinics
- Radiation Therapy Centres
By Country
-
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
Companies Mentioned
- Siemens Healthineers AG
- Accuray Incorporated
- Sumitomo Heavy Industries, Ltd.
- Elekta AB
- Hitachi, Ltd.
- Koninklijke Philips N.V.
- Brainlab AG
- Varian Medical Systems, Inc.
- Mevion Medical Systems
Asia Pacific Radiotherapy Market Strategic Insights
Asia Pacific Radiotherapy Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 1,242.1 Million |
| Market Size by 2028 | US$ 1,938.6 Million |
| CAGR (2021 - 2028) | 6.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
Asia Pacific Radiotherapy Market Country and Regional Insights
